Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Weber, H. P. Eulenbruch (Gerlingen, Germany). Is simvastatin a lung toxin? Clinical evidence for partially reversible interstitial lung disease after administration of simvastatin for hypercholesterinemia in ischemic vascular disease. Eur Respir J 2008; 32: Suppl. 52, 592

Member's Comments

No comment yet.

Related content which might interest you: A potential role for sildenafil in the management of pulmonary hypertension associated with parenchymal lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 The efficacy of pirfenidone in scleroderma related interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Is sildenafil an effective bridging therapy to lung transplantation for patients with pulmonary hypertension in the setting of lung disease? Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 Effect of PDE-5 inhibitor treatment in patients with interstitial lung disease and pulmonary hypertension Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011 Nintedanib has acute pulmonary vasodilatory effects in transgenic Fra2 mice with spontaneous progressive pulmonary hypertension and lung fibrosis. Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019 Year: 2019 Effect of baseline statin use on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016 Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 280s Year: 2004 Pulmonary function, oxidative stress and inflammatory markers in LPS-induced acute lung injury: Differential effects of atorvastatin, pravastatin and simvastatin Source: Annual Congress 2012 - Cell culture and animal models of lung disease Year: 2012 Severe pulmonary hypertension in lung disease: phenotypes and response to treatment Source: Eur Respir J 2015; 46: 1378-1389 Year: 2015 First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1701694; 10.1183/13993003.01694-2017 Year: 2018 Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD Source: Eur Respir J 2007; 29: 1115-1119 Year: 2007 Bosentan for sarcoidosis associated pulmonary arterial hypertension (BoSAPH) was effective in advanced parenchymal lung disease Source: Annual Congress 2012 - Sarcoidosis Year: 2012 Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy}, Source: Eur Respir J 2012; 40: 641-648 Year: 2012 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function Source: Eur Respir J 2016; 48: 843-851 Year: 2016 Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial Source: Eur Respir J 2013; 41: 853-860 Year: 2013 Endothelial dysfunction in patients with chronic obstructive pulmonary disease and concomitant arterial hypertension and its correction by telmisartan plus amlodipine fixed combination Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016